PLSEPulse Biosciences, Inc.
Is the business good?
Margins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is PLSE?
Pulse Biosciences, Inc. keeps −7008% of every revenue dollar as operating profit, against 6.6% for the median Medical Instruments & Supplies name.
Operating margin · Medical Instruments & Supplies median 6.6% · 12 months to Q2 2026
- R&D as % of revenue
- 4379%
R&D as % of revenue
- Gross margin
- 0.25%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −43829% |
| FY2021 | −4444% |
| FY2022 | −8294% |
| FY2025 | −21983% |
Details›
- Gross margin12 months to Q2 2026
- 0.25%
- Operating margin12 months to Q2 2026
- −7008%
- Net margin12 months to Q2 2026
- −6756%
- Free cash flow margin
- −5180%
- R&D as % of revenue
- 4379%
- Revenue, trailing twelve months
- $1.2M
- Free cash flow, trailing twelve months
- −$61M
- Net income, trailing twelve months
- −$80M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Medical Instruments & Supplies
Ranks #21 of 21 by RyuScore